Elanco Animal Health Incorporated (NYSE:ELAN) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have been given a consensus recommendation of “Hold” by the seven research firms that are currently covering the company, MarketBeat reports. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $15.17.

Several research firms recently commented on ELAN. Stifel Nicolaus decreased their price target on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, February 21st. Morgan Stanley decreased their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 26th. Barclays cut their price target on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Piper Sandler lowered their price objective on Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, March 6th. Finally, UBS Group cut their target price on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th.

Insider Buying and Selling

In other news, Director Lawrence Erik Kurzius acquired 10,000 shares of Elanco Animal Health stock in a transaction that occurred on Tuesday, March 11th. The shares were acquired at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the transaction, the director now directly owns 111,459 shares of the company’s stock, valued at approximately $1,136,881.80. The trade was a 9.86 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.57% of the stock is owned by corporate insiders.

Institutional Trading of Elanco Animal Health

Several hedge funds and other institutional investors have recently made changes to their positions in ELAN. Victory Capital Management Inc. increased its position in Elanco Animal Health by 10.2% in the 3rd quarter. Victory Capital Management Inc. now owns 102,414 shares of the company’s stock valued at $1,504,000 after acquiring an additional 9,480 shares during the period. Quest Partners LLC increased its holdings in Elanco Animal Health by 915.1% in the third quarter. Quest Partners LLC now owns 16,201 shares of the company’s stock valued at $238,000 after purchasing an additional 14,605 shares during the period. Commerce Bank raised its position in Elanco Animal Health by 2.2% during the 3rd quarter. Commerce Bank now owns 35,114 shares of the company’s stock worth $516,000 after purchasing an additional 741 shares during the last quarter. Bank of Montreal Can lifted its holdings in Elanco Animal Health by 3.5% during the 3rd quarter. Bank of Montreal Can now owns 416,336 shares of the company’s stock worth $5,962,000 after buying an additional 14,190 shares during the period. Finally, Qsemble Capital Management LP acquired a new position in Elanco Animal Health during the 3rd quarter worth about $264,000. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Stock Down 1.5 %

Shares of ELAN opened at $10.35 on Wednesday. The firm has a market cap of $5.12 billion, a P/E ratio of 25.86, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. Elanco Animal Health has a 52 week low of $10.03 and a 52 week high of $18.80. The firm’s 50-day simple moving average is $11.17 and its 200 day simple moving average is $12.37.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. Elanco Animal Health’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same quarter last year, the business posted $0.08 EPS. On average, analysts forecast that Elanco Animal Health will post 0.91 earnings per share for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.